homologous recombination repair deficiency
Foundation Medicine Nets FDA Approval for Tissue, Liquid NGS CDx for Lynparza Combo
The FDA approved FoundationOne CDx and FoundationOne Liquid for identifying BRCA1/2-mutated mCRPC patients eligible for Lynparza, Zytiga, and a steroid.
Io9 AI-Driven Digital Pathology Test Shows Potential to Inform Breast, Ovarian Cancer Therapy
Premium
The firm hopes to develop its DeepHRD digital pathology test as an alternative to costly companion diagnostics based on next-generation sequencing.
Mass General, Lunaphore Technologies to Develop Test to Predict PARP Inhibitor Response
The collaboration between Mass General and Switzerland's Lunaphore will initially focus on developing a test for ovarian, breast, and prostate cancers.
Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay
Under the terms of the deal, Illumina will develop a new HRD CDx for the EU and UK markets and a research-use only HRD assay that will be add-on content for its TSO 500 panel.
Myriad Genetics, Intermountain Healthcare Collaborate for Cancer Testing Service
The new service, slated for launch in the second half of 2021, will allow Myriad to expand its cancer tumor profiling services.